[go: up one dir, main page]

EE200200172A - Ühendid isheemia ravimiseks - Google Patents

Ühendid isheemia ravimiseks

Info

Publication number
EE200200172A
EE200200172A EEP200200172A EEP200200172A EE200200172A EE 200200172 A EE200200172 A EE 200200172A EE P200200172 A EEP200200172 A EE P200200172A EE P200200172 A EEP200200172 A EE P200200172A EE 200200172 A EE200200172 A EE 200200172A
Authority
EE
Estonia
Prior art keywords
ischemia
compounds
treatment
Prior art date
Application number
EEP200200172A
Other languages
English (en)
Estonian (et)
Inventor
Masamune Hiroko
Paul Deninno Michael
William Scott Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200172A publication Critical patent/EE200200172A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EEP200200172A 1999-09-30 2000-09-22 Ühendid isheemia ravimiseks EE200200172A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia

Publications (1)

Publication Number Publication Date
EE200200172A true EE200200172A (et) 2003-06-16

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200172A EE200200172A (et) 1999-09-30 2000-09-22 Ühendid isheemia ravimiseks

Country Status (41)

Country Link
EP (1) EP1216257B1 (xx)
JP (1) JP2003510331A (xx)
KR (1) KR100481605B1 (xx)
CN (1) CN1374967A (xx)
AP (1) AP2002002458A0 (xx)
AR (1) AR029887A1 (xx)
AT (1) ATE312117T1 (xx)
AU (1) AU778185B2 (xx)
BG (1) BG106636A (xx)
BR (1) BR0014384A (xx)
CA (1) CA2386079A1 (xx)
CO (1) CO5180581A1 (xx)
CR (1) CR6592A (xx)
CZ (1) CZ20021020A3 (xx)
DE (1) DE60024649D1 (xx)
EA (1) EA005422B1 (xx)
EC (1) ECSP003682A (xx)
EE (1) EE200200172A (xx)
GE (1) GEP20043241B (xx)
GT (1) GT200000161A (xx)
HK (1) HK1049011A1 (xx)
HR (1) HRP20020253A2 (xx)
HU (1) HUP0202807A3 (xx)
IL (1) IL148222A0 (xx)
IS (1) IS6286A (xx)
MA (1) MA26822A1 (xx)
MX (1) MXPA02003308A (xx)
MY (1) MY133996A (xx)
NO (1) NO20021474L (xx)
NZ (1) NZ517177A (xx)
OA (1) OA12021A (xx)
PA (1) PA8503301A1 (xx)
PE (1) PE20010696A1 (xx)
PL (1) PL357371A1 (xx)
SK (1) SK4182002A3 (xx)
TN (1) TNSN00191A1 (xx)
TR (1) TR200200843T2 (xx)
UA (1) UA73525C2 (xx)
WO (1) WO2001023399A1 (xx)
YU (1) YU23102A (xx)
ZA (1) ZA200202461B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
JP2005511590A (ja) * 2001-11-02 2005-04-28 アベンティス・ファーマスーティカルズ・インコーポレイテツド アデノシンａ１／ａ２アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
EP1687268A1 (en) * 2003-11-10 2006-08-09 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
KR20070085093A (ko) 2004-03-24 2007-08-27 파스젠, 엘엘씨. Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법
EA011097B1 (ru) 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006011130A1 (en) * 2004-07-28 2006-02-02 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren’s syndrome
WO2006015830A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
AU2005279209B2 (en) 2004-08-30 2011-03-24 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-BETA hydroxysteroid dehydrogenase inhibitors
ES2338441T3 (es) 2004-08-30 2010-05-07 Janssen Pharmaceutica Nv Derivados de n-2-adamantil-2-fenoxi-acetamida como inhibidores de 11-betahidroxiesteroide-deshidrogenasa.
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
EP2456419B1 (en) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
PE20170003A1 (es) 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
IN2012DN01453A (xx) 2009-08-20 2015-06-05 Novartis Ag
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
MX386250B (es) 2013-11-06 2025-03-18 Aeromics Inc Formulaciones novedosas.
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (xx) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
DE69428536T2 (de) * 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten

Also Published As

Publication number Publication date
PA8503301A1 (es) 2003-06-30
AP2002002458A0 (en) 2002-06-30
OA12021A (en) 2006-04-19
DE60024649D1 (de) 2006-01-12
ATE312117T1 (de) 2005-12-15
HK1049011A1 (zh) 2003-04-25
NO20021474L (no) 2002-05-22
YU23102A (sh) 2006-01-16
CR6592A (es) 2004-02-23
EA200200316A1 (ru) 2002-08-29
GEP20043241B (en) 2004-05-25
HRP20020253A2 (en) 2004-04-30
HUP0202807A3 (en) 2005-02-28
HUP0202807A2 (hu) 2002-12-28
BG106636A (bg) 2003-01-31
KR20020034206A (ko) 2002-05-08
NZ517177A (en) 2003-10-31
CN1374967A (zh) 2002-10-16
BR0014384A (pt) 2002-07-02
UA73525C2 (en) 2005-08-15
PE20010696A1 (es) 2001-07-05
EP1216257B1 (en) 2005-12-07
KR100481605B1 (ko) 2005-04-08
MXPA02003308A (es) 2002-10-04
WO2001023399A1 (en) 2001-04-05
CZ20021020A3 (cs) 2003-04-16
PL357371A1 (en) 2004-07-26
ZA200202461B (en) 2003-05-28
AR029887A1 (es) 2003-07-23
SK4182002A3 (en) 2003-04-01
AU7035200A (en) 2001-04-30
JP2003510331A (ja) 2003-03-18
EP1216257A1 (en) 2002-06-26
EA005422B1 (ru) 2005-02-24
TNSN00191A1 (fr) 2005-11-10
GT200000161A (es) 2002-03-22
MA26822A1 (fr) 2004-12-20
TR200200843T2 (tr) 2002-07-22
CO5180581A1 (es) 2002-07-30
MY133996A (en) 2007-11-30
IS6286A (is) 2002-02-26
AU778185B2 (en) 2004-11-18
NO20021474D0 (no) 2002-03-25
ECSP003682A (es) 2002-04-23
CA2386079A1 (en) 2001-04-05
IL148222A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
EE200200172A (et) Ühendid isheemia ravimiseks
EE200100502A (et) Ühendid
EE200100483A (et) Põletikuvastaste vahenditena kasutatavad ühendid
PT1202994E (pt) Novos compostos
EE200200224A (et) Uudsed ühendid
ZA991578B (en) Compounds for the treatment of ischemia.
ATE305470T1 (de) Naphthyridinverbindungen
DK1176964T3 (da) Brug af ET743 til behandling af cancer
IS6139A (is) Ný efnasambönd
NO20013769L (no) Kalsilytiske forbindelser
NO20020466D0 (no) Kalsilytiske forbindelser
PT1220858E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes virais
IS6141A (is) Ný efnasambönd
NO20014262D0 (no) Tiazoloindolinon-forbindelser
PT1175417E (pt) Compostos substituidos de benzolactamas
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
SE9903838D0 (sv) Novel compounds
SE9903080D0 (sv) Novel compounds
SE9904651D0 (sv) Novel compounds
SE9901270D0 (sv) Novel compounds
SE9901078D0 (sv) Novel compounds
SE9901117D0 (sv) Novel compounds
SE9901271D0 (sv) Novel compounds
SE9902194D0 (sv) Novel compounds